Biotech investment reaches fever pitch, but will it last?
Biotech M&A started off a bang this year and as the first half of the year has drawn to a close, biotech IPOs have reached a number that could see 2018 become a record-breaker.
Biotech M&A started off a bang this year and as the first half of the year has drawn to a close, biotech IPOs have reached a number that could see 2018 become a record-breaker.
BioNTech signed a collaboration agreement with Pfizer to conduct joint research on a mRNA-based flu vaccine.